Subscribe
shutterstock-173790782-web
360b / Shutterstock.com
10 September 2014Americas

Bristol-Myers Squibb hits Merck with cancer patent lawsuit

Bristol-Myers Squibb (BMS) has accused pharmaceutical company Merck of infringing a patent covering a method used to treat cancer.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Cancer centre sues BMS and Ono over alleged patent exploitation
25 June 2019   Boston-based Dana-Farber Cancer Institute is seeking a share of the $1.6 billion in licensing revenue that BMS and Ono Pharmaceutical Co have allegedly received from six immunotherapy patents.


Editor's picks

Europe
EPO report reveals leading tech investors in Europe
16 January 2025

Editor's picks

Europe
EPO report reveals leading tech investors in Europe
16 January 2025
Americas
EOFlow ordered to pay rival $452m over insulin patch trade secrets
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024

More on this story

Americas
Cancer centre sues BMS and Ono over alleged patent exploitation
25 June 2019   Boston-based Dana-Farber Cancer Institute is seeking a share of the $1.6 billion in licensing revenue that BMS and Ono Pharmaceutical Co have allegedly received from six immunotherapy patents.

More on this story

Americas
Cancer centre sues BMS and Ono over alleged patent exploitation
25 June 2019   Boston-based Dana-Farber Cancer Institute is seeking a share of the $1.6 billion in licensing revenue that BMS and Ono Pharmaceutical Co have allegedly received from six immunotherapy patents.

More features

Novartis stops rival’s launch of Entresto generic
Maucher Jenkins lands nine-strong team from rival boutique
EPO report reveals leading tech investors in Europe
K&L Gates adds litigator in Melbourne
Gowling WLG’s legal director jumps to Osborne Clarke
Novartis wins appeal in MSN clash over heart drug generic
Takeda loses AMR treatment patent used in kidney transplants
Withers & Rogers hires cell and gene therapy expert